Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.0%

9 terminated/withdrawn out of 50 trials

Success Rate

80.9%

-5.7% vs industry average

Late-Stage Pipeline

28%

14 trials in Phase 3/4

Results Transparency

42%

16 of 38 completed trials have results

Key Signals

16 with results9 terminated

Enrollment Performance

Analytics

Phase 2

23(47.9%)

Phase 1

10(20.8%)

Phase 4

9(18.8%)

Phase 3

5(10.4%)

N/A

1(2.1%)

48Total

Phase 2(23)

Phase 1(10)

Phase 4(9)

Phase 3(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (50)

Showing 20 of 50 trials

NCT04975152Phase 1Active Not Recruiting

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Role: collaborator

NCT00210249Completed

Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment

Role: collaborator

NCT00193128Phase 1Completed

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

Role: collaborator

NCT00210184Phase 2Completed

Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer

Role: collaborator

NCT02522572Phase 1Unknown

Quantitating the Impact of Plerixafor

Role: collaborator

NCT00525785Phase 2Completed

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)

Role: collaborator

NCT00256321Phase 2Terminated

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

Role: collaborator

NCT01136226Phase 4Completed

Evaluate Recovery of Testosterone for Patients Using Eligard

Role: collaborator

NCT00142480Phase 2Completed

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Role: collaborator

NCT03159143Phase 2Completed

Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract

Role: collaborator

NCT00075205Phase 2Completed

Rimonabant to Reduce Alcohol Consumption

Role: collaborator

NCT00977938Phase 4Completed

The Dual Antiplatelet Therapy Study (DAPT Study)

Role: collaborator

NCT00101075Phase 2Terminated

Title XELOX FOR SALIVARY GLAND CANCERS

Role: collaborator

NCT00526110Phase 1Completed

Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

Role: collaborator

NCT02049203Phase 1Completed

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

Role: collaborator

NCT00156533Phase 4Completed

Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing

Role: collaborator

NCT00169195Phase 2Completed

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Role: collaborator

NCT00152737Completed

Objective Evaluation of Proximal Ischemia

Role: collaborator

NCT00204061Phase 4Completed

Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis

Role: collaborator

NCT00240097Phase 2Completed

Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)

Role: collaborator